Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan acetate injection vs esomeprazole for peptic ulcer bleeding
CTR20220741Phase 2Completed
- Sponsor
- Nanjing Kefepin Shenghui Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vonoprazan in upper gastrointestinal bleeding (UGIB), Peptic ulcer disease (PUD), gastric ulcer and 1 more (3 arms), sponsored by Nanjing Kefepin Shenghui Pharmaceutical. Primary endpoint: Endoscopically confirmed no rebleeding within 72 hours after start of dosing. Started Mar 2022; status: completed.
02
Drugs
vonoprazan
03
Conditions
upper gastrointestinal bleeding (UGIB)Peptic ulcer disease (PUD)gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on CTR20220741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220741.